Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - December 2014

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the Month of December 2014
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2012-01063 Information regarding Onsolis, by Meda AB Inc. Disclosed in part 166
A-2012-01283 Documents with Apotex Inc. (Mar 14, 2012 to Apr 3 2012 and May 1, 2012. No records exist 0
A-2014-00063 Documents related to industrial wind turbines in wind energy for the project “Evidence of Negative Effects of Exposure to Infrasound on Animals” and “Evidence and Implications for Negative Effects of Exposure to Infrasound on Humans” (Jan 1, 2000 to May 8, 2014) Disclosed in part 226
A-2014-00294 Notice of Compliance with conditions (NOC/c) for Viramune. (NOC/c Sep 4, 1998). Disclosed in part 3
A-2014-00393 Marihuana for Medical Purposes Regulations documents for applications, security and quality assurance regarding the Ontario license producers Disclosed in part 1
A-2014-00527 Current claims services providers contract that First Nations and Inuit Health Branch - Non Insured Health Benefits has with Express Scripts Canada. Disclosed in part 383
A-2014-00529 Adverse Reaction Report (AER) for Mavik. Report number: E2B_00065907. All disclosed 21
A-2014-00538 Adverse Reaction Report (AER) for Humira. Report numbers: E2B_00069078, 000591180, 000586958. Disclosed in part 31
A-2014-00540 Adverse Reaction Report (AER) for Humira. Report numbers: 000584497, 000581248, 000594228. Disclosed in part 13
A-2014-00550 Marihuana for Medical Purposes Regulations documents for applications, business history and suitability, and reason for the May 9, 2014 recall notice by Peace Naturals production regarding license producers Peace Naturals Project Inc. Disclosed in part 71
A-2014-00617 Documents related to the problem of theft and misuse of narcotics from the hospital and government pharmacies in the Vancouver Coastal Health Authority, the Fraser Health Authority, Provincial Health Services, Providence Health Care, the Lower Mainland Pharmacy Services and the Fraser Authority’s Pharmacy Drug Distribution Centre. (Dec 1, 2011 to Aug 15, 2014) Disclosed in part 119
A-2014-00658 Documents regarding applications for licensed medical marihuana grow operations in Nova Scotia. Disclosed in part 7
A-2014-00668 Documents related to the inspection and results of inspections of CEN Biotech by Health Canada. All disclosed 13
A-2014-00674 A list of company names and contact information for all companies that have applied for a license to produce medical marijuana in Canada. (Jan 1, 2012 to Sep 8, 2014) Disclosed in part 8
A-2014-00712 Adverse Reaction Report (AER) for Cyclomen (Danazol). Report number: 000550448. Disclosed in part 4
A-2014-00721 Adverse Reaction Report (AER). Report numbers: 000511542 and 00550638. Disclosed in part 6
A-2014-00727 Adverse Reaction Report (AER). Report numbers: 000516861, 000528204, 000541718, 000555404 and 000568658. Disclosed in part 11
A-2014-00740 Adverse Reaction Report (AER) for Diabeta (Glibenclamide). Report number: 000522727 Disclosed in part 2
A-2014-00741 Adverse Reaction Report (AER) for Lantus (Glargine). Report number: E2B_00067062 Disclosed in part 9
A-2014-00752 Adverse Reaction Report (AER). Report number: 000606545. Disclosed in part 2
A-2014-00756 All documents in Ministerial Executive Correspondence System for the following files:
  • 13-118325-223 Proposed Approach for consultations on drug shortages
  • 13-116700-201 Results of Public Consultation and Next Steps re: Payment of Plasma Donors
  • 13-118686-295 British Columbia's compliance with the Canada Health Act
  • 13-116057-631 Medical Devices Single Audit Program
  • 13-117849-102 Budget 2014 Message
  • 13-117793-752 Marihuana Medical Access Program Price Increase
Disclosed in part 42
A-2014-00771 Adverse Reaction Report (AER) for Avastin. (Mar 31, 2014 to Oct 2, 2014). Disclosed in part 4
A-2014-00778 Documents related to Health Canada studies on wind turbine noise and the risk for human, animal, plant and aquatic species exposure at a distance of 550 metres and 2000 meters Disclosed in part 305
A-2014-00793 Adverse Reaction Report (AER). Report numbers: 000492528, 000495282 and 000518891 Disclosed in part 17
A-2014-00795 Documents related to priority setting exercise for Budget 1999 and 2000 related to requests for funding scientific and technological research, development, commercialization and innovation (Jan 1, 1997 to Dec 31, 1999) No records exist 0
A-2014-00799 Adverse Reaction Report (AER) for Lemtrada (Alemtuzumab). Report number: E2B_00051342. Disclosed in part 16
A-2014-00800 Adverse Reaction Report (AER) for Multaq (Dronedarone). Report number: 000582570. Disclosed in part 4
A-2014-00803 Adverse Reaction Report (AER) for Indapamide. Report numbers: 000608380, 000608956, 000609176, 000610857, E2B_00095854. Disclosed in part 21
A-2014-00829 Adverse Reaction Report (AER). Report number: 000489871, 000517919 and 000558399. Disclosed in part 4
A-2014-00843 Non-Insured Health Benefits reports that examine the financial resources required to provide an escort to First Nations women who are evacuated in pregnancy (Jan 1, 2000 to Oct 24, 2014 All disclosed 3
A-2014-00847 Documents related to the Toxicological studies for Hydrofluorosilicic acid being added to Toronto city water. (1963 to Oct 24, 2014) No records exist 0
A-2014-00849 Information regarding the medical device AVA 500 MPAT and AVA 500 SPAT (and SPAT ANGIO, SPAT E and SPAT L), License number 69124 by Bayer Medical Care Inc. Disclosed in part 32
A-2014-00850 Information regarding the medical device Stellant CT, License number 62683 by Bayer Medical Care Inc. Disclosed in part 52
A-2014-00862 Adverse Reaction Report (AER). Report numbers: 50000043282, 50000043283, 50000043281 and 50000043279. Disclosed in part 4
A-2014-00868 Information related to complaints, investigation and Health Canada’s instruction to the manufacturer of Sunbeam Heating Pads model #811. (Jan 1, 2001 to Oct 29, 2014) No records exist 0
A-2014-00884 A list of the Access to Information requests submitted to Health Canada on Human Papillomavirus vaccines or specifically Gardasil. (Jul 10, 2006 to Nov 30, 2014) All disclosed 12
A-2014-00897 List of all briefing material provided to the Deputy Minister and the Minister in October 2014. All disclosed 8
A-2014-00906 Adverse Reaction Report (AER) for Flagyl (Metronidazole). Report number: 000540441. Disclosed in part 1
A-2014-00912 Adverse Reaction Report (AER) for Taxotere (Docetaxel). Report number: 000590675. Disclosed in part 2
A-2014-00915 Adverse Reaction Report (AER) for Flagystatin (Metronidazole/Nystatin). Report number: 000587279. Disclosed in part 4
A-2014-00920 Adverse Reaction Report (AER) for Taxotere (Docetaxel). Report number: 000589042. Disclosed in part 1
A-2014-00923 Adverse Reaction Report (AER) for Plaquenil (Hydroxychloroquine Sulfate). Report number: 000550600 Disclosed in part 1
A-2014-00938 Adverse Reaction Report (AER) for PANTOLOC (Pantoprazole Sodium). Report numbers: 000585302, 000590289 and 000592848. Disclosed in part 4
A-2014-00940 Adverse Reaction Report (AER) for Actos (Pioglitazone). Report number: 000602543 Disclosed in part 1
A-2014-00941 Adverse Reaction Report (AER) for ONDISSOLVE ODF (Ondansetron). Report numbers: 000602412 and 000606476. Disclosed in part 2
A-2014-00943 Adverse Reaction Report (AER) for OMNARIS. Report numbers: 000600401, 000608357 and 000608857 Disclosed in part 6
A-2014-00947 Adverse Reaction Report (AER) for Feraheme (Ferumoxytol). Report numbers: 000598362, 000599507, 000600153, 000607679, 000607713 and 000613398 Disclosed in part 9
A-2014-00963 Adverse Reaction Report (AER) for GAM-352-14-CA. Report number: 000603927 Disclosed in part 1
A-2014-00965 Adverse Reaction Report (AER) for Cipralex (escitalopram). Report number: 000609223 Disclosed in part 2
A-2014-00972 Communications between the Minister and/or Deputy Minister and Doctors Without Borders/Mdecins Sans Frontires, Samaritan's Purse and/or the Canadian Red Cross. (Oct 26, 2014 to Nov 4, 2014) No records exist 0
A-2014-00984 Document related to the 45-day public consultation regarding the Proposed Registration Decision PRD2014-20, Flupyradi furone. (Nov 3, 2014) All disclosed 2
A-2014-00985 Adverse Reaction Report (AER) for Methadone/Methadose. Report numbers: 000602579, 000564860, 000502395, 000605325, 000567855, 000596740, 000587235, 000506888, 000558407, 000587985, 000528942, 000558354, 000588474, 000535383, 000499064, 000557090 and 000544494 Disclosed in part 20
A-2014-00986 Adverse Reaction Report (AER) for Optiray/Ioversol. Report numbers: 000329738, 000338819, 000347800, 000350300; 000350303, 000350304, 000350305, 000354807, 000362336, 000373471, 000373474, 000373477, 000373479, 000373480, 000385137, 000387212, 000406378, 000406388 000421921, 000536550, 000538849 000545076 and 000547883 Disclosed in part 23
A-2014-00987 Adverse Reaction Report (AER) for Gallium Citrate Ga-67 Injection. Report numbers: 000581319, 000595480, 000536157, 000469846, 000351095 and 000364935. Disclosed in part 7
A-2014-00992 Adverse Reaction Report (AER) for Telebrix 38 ORAL/Ioxithalamate. Report numbers: 000334779, 000418418 and 000609766. Disclosed in part 3
A-2014-00993 Adverse Reaction Report (AER) for TECHNETIUM TC 99M SESTAMIBI. Report numbers: 00334315, 000343638, 000347917, 000350780, 000363567, 000424361, 000428523, 000434626, 000436621 and 000502169. Disclosed in part 10
A-2014-00994 Adverse Reaction Report (AER) for OctreoScan. Report numbers: 000315458 and 000345110. Disclosed in part 2
A-2014-00998 Documents related to the contract signed with Resolve Research Solutions Inc., performance reviews of work done on behalf of Health Canada and expenses submitted by Celina Rayonne Ceasar-Chavannes. (Jan 1, 2010 to Nov 30, 2014) No records exist 0
A-2014-01000 Non-confidential documents related to the August 8, 2014, meeting between Julie Vaux, Chief of Staff Minister of Health Office and representatives of the Louisiana Pacific Corporation. No records exist 0
A-2014-01008 Communications to and from Deputy Health Minister’s office related to Canada’s visa suspension for people who have visited countries deemed by the World Health Organization as an “Ebola affected country”. (Aug 1, 2014 to Nov 14, 2014) No records exist 0
A-2014-01009 Communications to and from Health Minister’s office related to Canada’s visa suspension for people who have visited countries deemed by the World Health Organization as an “Ebola affected country”. (Aug 1, 2014 to Nov 14, 2014) No records exist 0
A-2014-01013 Documents to and from the Deputy Health Minister’s office related to Canada’s visa suspension for people who have visited countries deemed by the World Health Organization as an “Ebola affected country”. No records exist 0
A-2014-01014 Documents to and from the Health Minister’s office related to Canada’s visa suspension for people who have visited countries deemed by the World Health Organization as an “Ebola affected country”. No records exist 0
A-2014-01016 Documents related to the total number of registered populations for the drug benefit and for the medical supplies and equipment benefit paid to different service providers from each reserve in the province of Manitoba. (Jan 1, 2013 to Jan 31, 2013) Disclosed in part 14
A-2014-01032 Periodic Safety Update Report (PSUR) related to the drug Vyvanse. (Aug 1, 2009 to Feb 28, 2010) Disclosed in part 496
A-2014-01034 With relation to the E-Health Certification Service Program of Canada Health Infoway, list of certifications granted in the categories of Consumer Services Health Platform and Consumer Health Platform No records exist 0
A-2014-01040 Adverse Reaction Report (AER) for Eloxatin (oxaliplatin). Report number: 000602898. Disclosed in part 1
A-2014-01043 Adverse Reaction Report (AER) for Plavix (clopidogrel). Report number: 000598884. Disclosed in part 1
A-2014-01044 Adverse Reaction Report (AER) for Zopiclone. Report number: 000540029. Disclosed in part 2
A-2014-01046 Documents between Health Canada and the National Association of Pharmacy Regulatory Authority representatives pertaining to the issue of exempted codeine products (8 mg) sold without prescription and marketed in Canada
(Nov 1, 2001 to Dec 31, 2002)
No records exist 0
A-2014-01057 Documents relating to the total amount of funding Health Canada supplied through the National Native Alcohol and Drug Abuse Program to the reserves: Attawapiskat, Kashechewan, Fort Abany, Moose Cree, Moosonee, and Peawanuk/Weenusk. (Jan 1, 2000 to Dec 31, 2014) All disclosed 1
A-2014-01060 Letter issued prior to June 12, 2013from Therapeutic Products Directorate to Auro Pharma Inc. certifying that the examination of Auro-Atorvastatin (Atorvastatin Calcium) 10, 20, 40 and 80 mg was complete. No records exist 0
A-2014-01061 Letter issued prior to December 21, 2012 from Therapeutic Products Directorate to Mint Pharmaceutical Inc. certifying that the examination of Mint-Atorvastatin (Atorvastatin Calcium) 10, 20, 40 and 80 mg was complete. No records exist 0
A-2014-01063 Letter issued prior to December 21, 2012 from Therapeutic Products Directorate to Accel Pharma Inc. certifying that the examination of Accel-Atorvastatin (Atorvastatin Calcium) 10, 20, 40 and 80 mg was complete. No records exist 0
A-2014-01064 Letter issued prior to August 20, 2012 from Therapeutic Products Directorate to Jamp Pharma Corporation certifying that the examination of Jamp-Atorvastatin (Atorvastatin Calcium) 10, 20, 40 and 80 mg was complete. No records exist 0
A-2014-01069 Letter issued prior to August 25, 2016 from Therapeutic Products Directorate to Dominion Pharmacal certifying that the examination of Dom-Atorvastatin (Atorvastatin Calcium) 10, 20, 40 and 80 mg was complete. No records exist 0
A-2014-01074 Letter issued prior to August 29, 2013 from Therapeutic Products Directorate to Sivern Pharmaceuticals ULC certifying that the examination of Atorvastatin (alorvastatin calcium/ altorvastatin calcium propylene glycol) 10, 20, 40 and 80 mg was complete. No records exist 0
A-2014-01078 Adverse Reaction Reports (AER) number: 000604459, 000599528, 000599708, 000603587 and 000613931 Disclosed in part 19
A-2014-01083 Documents related to the Blacklock’s Reporter subscription in the name alberta.newsdips@hc-sc.g.ca (Feb 9, 2014 to Dec 1, 2014) No records exist 0
A-2014-01088 Documents regarding who authorized the release of the Health Canada Wind Turbine Noise and Health Study Summary of Results (Nov 6, 2014) All disclosed 7
A-2014-01089 Documents regarding the names of those who drafted the summary results related to the Health Canada Wind Turbine Noise and Health Study Summary Key Findings brochure. (Nov 11, 2014) Disclosed in part 29
A-2014-01090 Documents regarding who authorized the release of the Health Canada Wind Turbine Noise and Health Study Summary Key Findings brochure (Nov 1, 2014) Disclosed in part 3
A-2014-01092 Documents regarding the Health Canada Wind Turbine Noise and Health Study Summary of Results from the office of the Prime Minister and the Minister of Health (Nov 6, 2014) All disclosed 23
A-2014-01093 Documents related to the Interdepartmental Wind Technology Road Map Committee, its composition and activities. All disclosed 1
A-2014-01104 A listing of the Access to Information requests submitted to Health Canada. (Nov 1, 2014 to Nov 30, 2014). Disclosed in part 17